The introduction of small molecule inhibitors of BTK and BCL-2 has dramatically improved the prognosis of CLL and increased the understanding of CLL pathobiology, but drug resistance may occur, resulting in a lack of disease control and unmet medical needs [2,3]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.